Theravance Biopharma TBPH Receivables From Milestone And Royalty Assets Current

Receivables From Milestone And Royalty Assets Current at other companies

XOMA CorporationXOMA

$3.7M+12.0%

OmerosOMER

$25.48M-12.8%

Axsome TherapeuticsAXSM

$1.8M+63.2%

Dianthus TherapeuticsDNTH

$15M0.0%

Protagonist TherapeuticsPTGX

$53.66M—

Revolution Medicines, Inc.RVMD

$280.64M—

Other financials

Income statement

See full

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Cash flow

See full

Operating cash flow$73.3M+70.3%

CapEx$8.0K-95.8%

Free cash flow$59.6M+5,560%

Valuation

See full

Market cap$896.51M+68.7%

Enterprise value$648.91M+38.3%

P/E7.8×—

P/S8.2×0.0×

Profitability

See full

Gross margin60.8%—

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

FCF margin221.9%+206pp

Returns & leverage

See full

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept tbph:ReceivablesFromMilestoneAndRoyaltyAssetsCurrent.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's receivables from milestone and royalty assets current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's receivables from milestone and royalty assets current?: Theravance Biopharma (TBPH) reported receivables from milestone and royalty assets current of $50M in Q4 2025.
What does receivables from milestone and royalty assets current mean?: This metric captures the short-term receivables specifically tied to earned but uncollected milestone payments and royalty revenues from licensed intellectual property. It serves as a key indicator of the company's success in achieving clinical or commercial targets that trigger contractual payments. High balances indicate successful product commercialization or development progress that will soon convert to cash.